



Australian Government

Department of Health and Aged Care
Office of the Gene Technology Regulator

**Invitation to comment on a trial
of a genetically modified vaccine against devil facial tumour disease in
Tasmanian devils.**

The Gene Technology Regulator is assessing an application from the University of Tasmania to conduct a trial, under limited and controlled conditions, of a genetically modified (GM) vaccine for the prevention and/or treatment of devil facial tumour disease in Tasmanian devils. The GM vaccine would be administered to Tasmanian devils kept in enclosures within trial sites in Tasmania.

The Regulator has prepared a Risk Assessment and Risk Management Plan (RARMP) for this application and welcomes written submissions relating to the protection of human health and safety and the environment prior to making a decision on whether to issue the licence. The consultation RARMP and related information can be obtained via our website (search for [DIR 195](#)), or from the contacts below. Submissions should reference DIR 195 and be received by **12 May 2023**.

Office of the Gene Technology Regulator
MDP 54 GPO Box 9848 CANBERRA ACT 2601
Telephone: 1800 181 030 Website: www.ogtr.gov.au
E-mail: ogtr@health.gov.au